百奥泰：近日收到Intas支付的540.00万美元里程碑付款

Core Viewpoint - The company announced the approval of a licensing and commercialization agreement for BAT2506 (Golimumab) during its first extraordinary general meeting of 2025, which will take effect immediately [1] Group 1: Financial Details - The company received a milestone payment of $5.4 million from Intas, after deducting $600,000 for corporate income tax, resulting in a net amount that will be further reduced by bank fees [1] - The total amount received in RMB is approximately 38.36 million, calculated using the exchange rate of 7.1034 RMB per USD as of September 11, 2025 [1] Group 2: Regulatory Status - As of the date of the announcement, the company has submitted applications for the marketing authorization of BAT2506 (Golimumab) to the National Medical Products Administration (NMPA) in China, the U.S. Food and Drug Administration (FDA), and the European Medicines Agency (EMA), all of which have been accepted [1]